{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:30:25Z","timestamp":1793345425168,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11523-025-01180-2","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:32:10Z","timestamp":1761582730000},"page":"1015-1022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cardiotoxicity Profiles of Osimertinib Compared with Other EGFR Tyrosine Kinase Inhibitors: A Real-World Comparative Incidence Analysis"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5633-687X","authenticated-orcid":false,"given":"Zaid","family":"Muhanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-8468","authenticated-orcid":false,"given":"Muntaser","family":"Al Zyoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3102-808X","authenticated-orcid":false,"given":"Ahmad","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4205-8417","authenticated-orcid":false,"given":"Muhammad","family":"Awidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"1180_CR1","unstructured":"Cancer Facts & Figures 2025. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/2025-cancer-facts-figures.html. Accessed 13 May 2025"},{"key":"1180_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"1180_CR3","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"Y-L Zhang","year":"2016","unstructured":"Zhang Y-L, Yuan J-Q, Wang K-F, Fu X-H, Han X-R, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985\u201393. https:\/\/doi.org\/10.18632\/oncotarget.12587.","journal-title":"Oncotarget"},{"key":"1180_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","volume":"26","author":"B Melosky","year":"2022","unstructured":"Melosky B, Kambartel K, H\u00e4ntschel M, Bennetts M, Nickens DJ, Brinkmann J, et al. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. Mol Diagn Ther. 2022;26:7\u201318. https:\/\/doi.org\/10.1007\/s40291-021-00563-1.","journal-title":"Mol Diagn Ther"},{"key":"1180_CR5","unstructured":"Non\u2013Small Cell Lung Cancer, Version 4.2024. NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2024;22(4). https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/4\/article-p249.xml. Accessed 13 May 2025"},{"key":"1180_CR6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11523-021-00839-w","volume":"16","author":"YN Lamb","year":"2021","unstructured":"Lamb YN. Osimertinib: a review in previously untreated, EGFR mutation-positive, advanced NSCLC. Target Oncol. 2021;16:687\u201395. https:\/\/doi.org\/10.1007\/s11523-021-00839-w.","journal-title":"Target Oncol"},{"key":"1180_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jtho.2024.10.003","volume":"20","author":"M Bak","year":"2025","unstructured":"Bak M, Park H, Lee S-H, Lee N, Ahn M-J, Ahn JS, et al. The risk and reversibility of osimertinib-related cardiotoxicity in a real-world population. J Thorac Oncol. 2025;20:167\u201376. https:\/\/doi.org\/10.1016\/j.jtho.2024.10.003.","journal-title":"J Thorac Oncol"},{"key":"1180_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2025.06.011","author":"Y Tatebe","year":"2025","unstructured":"Tatebe Y, Tanaka Y, Manabe Y, Okano S, Higashionna T, Hamano H, et al. Risk of heart failure hospitalization in patients treated with osimertinib: a population-based retrospective cohort study. JACC CardioOncol. 2025;7(6):738-748.\u00a0https:\/\/doi.org\/10.1016\/j.jaccao.2025.06.011.","journal-title":"JACC CardioOncol."},{"issue":"2","key":"1180_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","volume":"1","author":"K Anand","year":"2019","unstructured":"Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-induced cardiotoxicity. JACC CardioOncol. 2019;1(2):172\u20138. https:\/\/doi.org\/10.1016\/j.jaccao.2019.10.006.","journal-title":"JACC CardioOncol"},{"key":"1180_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1619517","author":"W Wang","year":"2025","unstructured":"Wang W, Liu H, Wen Y, Zhang Y, Ma X. An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib. Front Pharmacol. 2025;16:1619517.\u00a0https:\/\/doi.org\/10.3389\/fphar.2025.1619517.","journal-title":"Front Pharmacol"},{"key":"1180_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1200\/JCO.20.01171","volume":"39","author":"MS Ewer","year":"2021","unstructured":"Ewer MS, Tekumalla SH, Walding A, Atuah KN. Cardiac safety of osimertinib: a review of data. J Clin Oncol. 2021;39:328\u201337. https:\/\/doi.org\/10.1200\/JCO.20.01171.","journal-title":"J Clin Oncol"},{"key":"1180_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.48364","volume":"7","author":"C-Y Lin","year":"2024","unstructured":"Lin C-Y, Chang W-T, Su P-L, Kuo C-W, Yang J, Lin C-C, et al. Cardiac events and survival in patients with EGFR-mutant non-small cell lung cancer treated with Osimertinib. JAMA Netw Open. 2024;7:e2448364. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.48364.","journal-title":"JAMA Netw Open"},{"key":"1180_CR13","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1016\/j.jtho.2021.07.030","volume":"16","author":"S Waliany","year":"2021","unstructured":"Waliany S, Zhu H, Wakelee H, Padda SK, Das M, Ramchandran K, et al. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC. J Thorac Oncol. 2021;16:2029\u201339. https:\/\/doi.org\/10.1016\/j.jtho.2021.07.030.","journal-title":"J Thorac Oncol"},{"key":"1180_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082834","volume":"390","author":"Z Ma","year":"2025","unstructured":"Ma Z, Cao F, Liao M, Min R, Zheng R, Sun X, et al. Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis. BMJ. 2025;390:e082834. https:\/\/doi.org\/10.1136\/bmj-2024-082834.","journal-title":"BMJ"},{"key":"1180_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108629","author":"CS Gawli","year":"2025","unstructured":"Gawli CS, Patil BR, Nagpure NR, Patil CR, Kumar A, Patel HM. Prevalence of osimertinib-induced cardiotoxicity in non-small cell lung cancer patients: a systematic review and meta-analysis. Lung Cancer. 2025;205:108629. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108629.","journal-title":"Lung Cancer"},{"key":"1180_CR16","doi-asserted-by":"publisher","first-page":"1177003","DOI":"10.3389\/fphar.2023.1177003","volume":"14","author":"P Li","year":"2023","unstructured":"Li P, Tian X, Wang G, Jiang E, Li Y, Hao G. Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels. Front Pharmacol. 2023;14:1177003. https:\/\/doi.org\/10.3389\/fphar.2023.1177003.","journal-title":"Front Pharmacol"},{"key":"1180_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/j.1552-4604.1984.tb01822.x","volume":"24","author":"EMV Williams","year":"1984","unstructured":"Williams EMV. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24:129\u201347. https:\/\/doi.org\/10.1002\/j.1552-4604.1984.tb01822.x.","journal-title":"J Clin Pharmacol"},{"key":"1180_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccep.2010.10.012","volume":"3","author":"C Antzelevitch","year":"2011","unstructured":"Antzelevitch C, Burashnikov A. Overview of basic mechanisms of cardiac arrhythmia. Card Electrophysiol Clin. 2011;3:23\u201345. https:\/\/doi.org\/10.1016\/j.ccep.2010.10.012.","journal-title":"Card Electrophysiol Clin"},{"key":"1180_CR19","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1056\/NEJMoa043938","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, Zelenkofske S, McMurray JJV, Finn PV, Velazquez E, Ertl G, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581\u20138. https:\/\/doi.org\/10.1056\/NEJMoa043938.","journal-title":"N Engl J Med"},{"key":"1180_CR20","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DAE Cross","year":"2014","unstructured":"Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046\u201361. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0337.","journal-title":"Cancer Discov"},{"key":"1180_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1161\/CIRCULATIONAHA.107.690487","volume":"116","author":"K Lemmens","year":"2007","unstructured":"Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1\/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation. 2007;116:954\u201360. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.690487.","journal-title":"Circulation"},{"key":"1180_CR22","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10741-020-10072-8","volume":"26","author":"D Gonciar","year":"2021","unstructured":"Gonciar D, Mocan L, Zlibut A, Mocan T, Agoston-Coldea L. Cardiotoxicity in HER2-positive breast cancer patients. Heart Fail Rev. 2021;26:919\u201335. https:\/\/doi.org\/10.1007\/s10741-020-10072-8.","journal-title":"Heart Fail Rev"},{"key":"1180_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029927","volume":"101","author":"C Castillo","year":"2022","unstructured":"Castillo C, Camejo N, Etcheverria C, Ferradaz J, Ferreira A, Fontan A, et al. Trastuzumab-induced cardiotoxicity in early breast cancer over a 10-year period in Uruguay. Medicine (Baltimore). 2022;101:e29927. https:\/\/doi.org\/10.1097\/MD.0000000000029927.","journal-title":"Medicine (Baltimore)"},{"key":"1180_CR24","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1177\/10781552231193149","volume":"30","author":"SA Alowais","year":"2024","unstructured":"Alowais SA, Luk SO, Kim EB, Alsuhebany N, Zangardi M. Late-onset cardiotoxicity in patients with HER2-positive metastatic breast cancer receiving trastuzumab-based therapy. J Oncol Pharm Pract. 2024;30:992\u20138. https:\/\/doi.org\/10.1177\/10781552231193149.","journal-title":"J Oncol Pharm Pract"},{"key":"1180_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1634\/theoncologist.2015-0230","volume":"21","author":"SC Seferina","year":"2016","unstructured":"Seferina SC, Boer M, Derksen MW, Berkmortel F, Kampen RJW, Wouw AJ, et al. Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily Dutch practice: a study of the Southeast Netherlands Breast Cancer Consortium. Oncologist. 2016;21:555\u201362. https:\/\/doi.org\/10.1634\/theoncologist.2015-0230.","journal-title":"Oncologist"},{"key":"1180_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","volume":"18","author":"L Tarantini","year":"2012","unstructured":"Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail. 2012;18:113\u20139. https:\/\/doi.org\/10.1016\/j.cardfail.2011.10.015.","journal-title":"J Card Fail"},{"key":"1180_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejmech.2017.04.036","volume":"135","author":"H Zhang","year":"2017","unstructured":"Zhang H, Wu W, Feng C, Liu Z, Bai E, Wang X, et al. Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R\/T790M double mutants. Eur J Med Chem. 2017;135:12\u201323. https:\/\/doi.org\/10.1016\/j.ejmech.2017.04.036.","journal-title":"Eur J Med Chem"},{"key":"1180_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.yjmcc.2009.07.026","volume":"48","author":"J-P Benitah","year":"2010","unstructured":"Benitah J-P, Alvarez JL, G\u00f3mez AM. L-type Ca2+ current in ventricular cardiomyocytes. J Mol Cell Cardiol. 2010;48:26\u201336. https:\/\/doi.org\/10.1016\/j.yjmcc.2009.07.026.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"1180_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02838-2","volume":"21","author":"H Wang","year":"2023","unstructured":"Wang H, Wang Y, Li J, He Z, Boswell SA, Chung M, et al. Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes. BMC Med. 2023;21(1):147. https:\/\/doi.org\/10.1186\/s12916-023-02838-2.","journal-title":"BMC Med"},{"key":"1180_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"},{"key":"1180_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6279","volume":"10","author":"Y Fukuda","year":"2022","unstructured":"Fukuda Y, Kawa Y, Nonaka A, Shiotani H. Reoccurrence of takotsubo cardiomyopathy induced by osimertinib: a case report. Clin Case Rep. 2022;10:e6279. https:\/\/doi.org\/10.1002\/ccr3.6279.","journal-title":"Clin Case Rep"},{"key":"1180_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58020312","volume":"58","author":"A Fukuo","year":"2022","unstructured":"Fukuo A, Imamura T, Onoda H, Kinugawa K. Successful management of Osimertinib-induced heart failure. Medicina (Mex). 2022;58:312. https:\/\/doi.org\/10.3390\/medicina58020312.","journal-title":"Medicina (Mex)"},{"key":"1180_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jaccas.2019.12.038","volume":"2","author":"SR Patel","year":"2020","unstructured":"Patel SR, Brown S-AN, Kubusek JE, Mansfield AS, Duma N. Osimertinib-induced cardiomyopathy. JACC Case Rep. 2020;2:641\u20135. https:\/\/doi.org\/10.1016\/j.jaccas.2019.12.038.","journal-title":"JACC Case Rep"},{"key":"1180_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jaccao.2020.01.003","volume":"2","author":"AJ Piper-Vallillo","year":"2020","unstructured":"Piper-Vallillo AJ, Costa DB, Sabe MA, Asnani A. Heart failure associated with the epidermal growth factor receptor inhibitor osimertinib. JACC CardioOncol. 2020;2:119\u201322. https:\/\/doi.org\/10.1016\/j.jaccao.2020.01.003.","journal-title":"JACC CardioOncol"},{"key":"1180_CR35","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.122.009078","volume":"16","author":"BA Bates","year":"2023","unstructured":"Bates BA, Akhabue E, Nahass MM, Mukherjee A, Hiltner E, Rock J, et al. Validity of international classification of diseases (ICD)-10 diagnosis codes for identification of acute heart failure hospitalization and heart failure with reduced versus preserved ejection fraction in a national Medicare sample. Circ Cardiovasc Qual Outcomes. 2023;16:e009078. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.122.009078.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1180_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70179","volume":"34","author":"J Slezak","year":"2025","unstructured":"Slezak J, Bruxvoort KJ, Sy LS, Ackerson BK, Shen AY-J, Lee M, et al. Validation of ICD-10 diagnosis codes for identification of acute myocardial infarction from a US integrated healthcare system. Pharmacoepidemiol Drug Saf. 2025;34:e70179. https:\/\/doi.org\/10.1002\/pds.70179.","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01180-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01180-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01180-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:10:24Z","timestamp":1764605424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01180-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1180"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01180-2","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Zaid Muhanna, Muntaser Al Zyoud, Ahmad Issa, and Muhammad Awidi declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study used fully de-identified data from the TriNetX Global Collaborative Network. As no identifiable private information was accessed, institutional review board (IRB) approval was not required. The analysis was conducted in compliance with HIPAA regulations and adhered to the ethical principles of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was not required for this study due to the use of a fully de-identified patient database.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data used in this article may be made available upon reasonable request from the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Zaid Muhanna: Conceptualization, Investigation, Methodology, Writing\u2014original draft. Muntaser Al Zyoud: Investigation, Data curation, Formal analysis, Writing\u2014review and editing. Ahmad Issa: Investigation, Conceptualization, Writing\u2014original draft. Muhammad Awidi: Conceptualization, Investigation, Supervision, Writing\u2014review and editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}